ABEO
Price
$6.96
Change
+$0.11 (+1.61%)
Updated
Sep 3, 04:59 PM (EDT)
Capitalization
356.9M
74 days until earnings call
ZYME
Price
$14.14
Change
+$0.13 (+0.93%)
Updated
Sep 3 closing price
Capitalization
1.07B
Interact to see
Advertisement

ABEO vs ZYME

Header iconABEO vs ZYME Comparison
Open Charts ABEO vs ZYMEBanner chart's image
Abeona Therapeutics
Price$6.96
Change+$0.11 (+1.61%)
Volume$17.02K
Capitalization356.9M
Zymeworks
Price$14.14
Change+$0.13 (+0.93%)
Volume$715.18K
Capitalization1.07B
ABEO vs ZYME Comparison Chart in %
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. ZYME commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Hold and ZYME is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ABEO: $6.85 vs. ZYME: $14.01)
Brand notoriety: ABEO and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 74% vs. ZYME: 144%
Market capitalization -- ABEO: $356.9M vs. ZYME: $1.07B
ABEO [@Biotechnology] is valued at $356.9M. ZYME’s [@Biotechnology] market capitalization is $1.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABEO and ZYME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 3 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).

  • ABEO’s TA Score: 3 bullish, 5 bearish.
  • ZYME’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than ABEO.

Price Growth

ABEO (@Biotechnology) experienced а -3.66% price change this week, while ZYME (@Biotechnology) price change was -5.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

ABEO is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZYME($1.07B) has a higher market cap than ABEO($357M). ABEO YTD gains are higher at: 22.980 vs. ZYME (-4.303). ABEO has higher annual earnings (EBITDA): 80M vs. ZYME (-69.77M). ZYME has more cash in the bank: 281M vs. ABEO (226M). ZYME has less debt than ABEO: ZYME (18.7M) vs ABEO (24.1M). ZYME has higher revenues than ABEO: ZYME (123M) vs ABEO (400K).
ABEOZYMEABEO / ZYME
Capitalization357M1.07B33%
EBITDA80M-69.77M-115%
Gain YTD22.980-4.303-534%
P/E Ratio10.88N/A-
Revenue400K123M0%
Total Cash226M281M80%
Total Debt24.1M18.7M129%
FUNDAMENTALS RATINGS
ABEO vs ZYME: Fundamental Ratings
ABEO
ZYME
OUTLOOK RATING
1..100
7412
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2096
PRICE GROWTH RATING
1..100
4743
P/E GROWTH RATING
1..100
5462
SEASONALITY SCORE
1..100
1050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZYME's Valuation (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABEO (81) in the Pharmaceuticals Generic industry. This means that ZYME’s stock grew somewhat faster than ABEO’s over the last 12 months.

ZYME's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that ZYME’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's SMR Rating (20) in the Pharmaceuticals Generic industry is significantly better than the same rating for ZYME (96) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew significantly faster than ZYME’s over the last 12 months.

ZYME's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as ABEO (47) in the Pharmaceuticals Generic industry. This means that ZYME’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's P/E Growth Rating (54) in the Pharmaceuticals Generic industry is in the same range as ZYME (62) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew similarly to ZYME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOZYME
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAFCX36.06N/A
N/A
Fidelity Advisor Financials C
FDVLX14.48N/A
N/A
Fidelity Value
AXVNX19.14-0.10
-0.52%
Acclivity Small Cap Value N
SDVGX17.32-0.10
-0.57%
Sit Dividend Growth I
ITYAX67.16-0.60
-0.89%
Invesco Technology A

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ZYME. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+0.29%
ZYME - ABEO
48%
Loosely correlated
-5.40%
IPSC - ABEO
43%
Loosely correlated
-3.23%
CRNX - ABEO
43%
Loosely correlated
+7.45%
ELVN - ABEO
42%
Loosely correlated
+3.06%
OCUL - ABEO
42%
Loosely correlated
+4.01%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with CRNX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
-5.40%
CRNX - ZYME
49%
Loosely correlated
+7.45%
NRIX - ZYME
49%
Loosely correlated
-2.46%
ABEO - ZYME
48%
Loosely correlated
+0.29%
XNCR - ZYME
47%
Loosely correlated
+5.17%
ELVN - ZYME
47%
Loosely correlated
+3.06%
More